Nephrogenic Diabetes Insipidus
Nephrogenic diabetes insipidus (NDI) is a disorder in which the kidneys cannot concentrate urine despite adequate or elevated levels of antidiuretic hormone (ADH/vasopressin). This distinguishes NDI from central diabetes insipidus (DI; inadequate ADH production) and primary polydipsia.
Table of Contents
Overview and Mechanism of Action
Normal urine concentration depends on the vasopressin (ADH) signaling pathway in the renal collecting duct. When plasma osmolality rises, a tightly coordinated cascade activates:
- ADH is released from the posterior pituitary.
- ADH binds the V2 receptor (AVPR2) on principal cells of the collecting duct.
- Gs protein activation stimulates adenylyl cyclase, producing cyclic AMP (cAMP).
- cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) vesicles.
- Phosphorylated AQP2 inserts into the apical membrane, allowing water reabsorption from the tubular lumen into the medullary interstitium.
NDI represents a defect anywhere in this pathway: V2 receptor mutation (most common hereditary cause), AQP2 mutation, or acquired disruption from agents such as lithium or hypercalcemia. The result is persistent production of large volumes of dilute urine regardless of the patient's hydration status or measured ADH levels. Crucially, ADH levels are elevated in NDI (the kidney does not respond) in contrast to central DI (where ADH production is insufficient).
A newer name. A 2025 international expert consensus statement calls congenital NDI by a second name, arginine vasopressin resistance, describing it as a rare inherited disorder in which the far end of the kidney tubule does not respond to vasopressin, so the kidney loses its ability to concentrate urine; the result is heavy urination (polyuria), heavy thirst (polydipsia) and a risk of dangerous dehydration with high blood salt (hypertonic dehydration). The statement, written by children’s and adult kidney specialists, urologists, clinical geneticists and patient advocates, sets out 36 recommendations covering diagnosis, treatment and follow-up in children and adults, emergency care, genetic counselling and family planning (Levtchenko 2025).
Inherited Nephrogenic Diabetes Insipidus
Two distinct genetic forms account for virtually all congenital NDI:
X-Linked NDI (AVPR2 Mutations, ~90% of Congenital NDI)
The AVPR2 gene encodes the V2 receptor. X-linked recessive inheritance means males are fully affected from birth with severe polyuria, while females show variable penetrance due to X-inactivation — some are clinically normal, others exhibit mild polyuria. Over 300 pathogenic AVPR2 mutations have been described, including missense, nonsense, frameshift, and splice-site variants.
Severely affected male infants present with unexplained high fever, irritability, poor feeding, dehydration, and hypernatremia. If unrecognized, severe hypernatremia causes seizures, intracranial hemorrhage, and death. Prompt recognition and treatment are life-saving.
Autosomal NDI (AQP2 Mutations, ~10% of Congenital NDI)
Mutations in the AQP2 gene encoding aquaporin-2 cause autosomal NDI in either dominant or recessive patterns. Dominant AQP2 mutations typically affect the C-terminus trafficking domain, disrupting AQP2 vesicle insertion even when the dominant allele is expressed. Recessive mutations generally eliminate functional protein from both alleles.
Acquired Causes of NDI
Acquired NDI is far more common than the inherited forms in clinical practice. Major causes include:
- Lithium (most important acquired cause — see dedicated section below).
- Chronic kidney disease: tubulointerstitial damage reduces AQP2 expression in the collecting duct, impairing concentrating ability progressively.
- Hypercalcemia: serum calcium above 11 mg/dL activates the calcium-sensing receptor (CaSR) in the collecting duct, downregulating AQP2 and inhibiting the cAMP pathway; renal vasoconstriction further worsens medullary function. Partially reversible with calcium normalization.
- Hypokalemia (severe and prolonged): potassium below 2.5 mEq/L leads to tubulointerstitial nephritis and AQP2 downregulation; seen in undertreated Bartter or Gitelman syndrome.
- Sickle cell disease: sickling in the vasa recta causes papillary ischemia and destruction of the medullary concentrating gradient.
- Infiltrative diseases: sarcoidosis, amyloidosis, and multiple myeloma can physically destroy collecting duct architecture.
- Drugs: demeclocycline (intentionally exploited to treat the syndrome of inappropriate antidiuretic hormone secretion, SIADH, via induced NDI), amphotericin B, foscarnet, ifosfamide, and cidofovir.
- Post-obstructive uropathy: bilateral ureteral obstruction relief causes transient tubular dysfunction; usually self-limited over days to weeks.
Lithium-Induced NDI
Lithium-induced NDI is the single most common acquired cause of NDI encountered clinically, given the widespread use of lithium for bipolar disorder.
Mechanism
Lithium enters collecting duct principal cells via the epithelial sodium channel (ENaC). Once intracellular, lithium inhibits two critical targets: glycogen synthase kinase-3 beta (GSK-3β) and adenylyl cyclase. The net effect is a profound reduction in cAMP production combined with impaired AQP2 phosphorylation, rendering the collecting duct resistant to ADH regardless of circulating vasopressin levels.
Epidemiology and Course
A 1987 analysis of published studies estimated that at least 54% of 1,105 unselected people on long-term lithium had an impaired ability to concentrate urine, and that this showed up as overt heavy urination (polyuria) in 19% (Boton 1987). The same analysis found kidney filtration (glomerular filtration rate) normal in 85% of 1,172 lithium users, with the remaining 15% showing only a mild reduction, clustering at about 60 mL/min. Severity correlates with cumulative duration of therapy and with higher serum lithium levels. After lithium discontinuation, NDI can persist for months to years; patients with prolonged, high-dose exposure may have permanent concentrating defects due to irreversible tubulointerstitial fibrosis.
Management of Lithium-Induced NDI
- Amiloride: first-line agent; blocks ENaC and thereby reduces lithium entry into principal cells, preventing further accumulation and allowing partial AQP2 recovery. Also potassium-sparing, counteracting thiazide-induced hypokalemia. Boton 1987 lists its advantages over thiazides: it only weakly increases salt loss in the urine, so it is less likely to raise blood lithium levels by drying the body out (volume contraction), and by conserving potassium it removes the need for the potassium supplements usually required when thiazides are used for lithium-induced polyuria.
- Thiazide diuretic: reduces urine volume via paradoxical mechanism (see Treatment section).
- Indomethacin: inhibits prostaglandin E2, enhancing residual ADH sensitivity.
- Low-sodium diet: reduces osmotic load and amplifies thiazide effect.
- Lithium levels: more severe NDI goes with longer lithium use and higher blood lithium levels (see above). Stopping lithium abruptly carries a risk of bipolar relapse.
Clinical Presentation
Polyuria and Polydipsia
Polyuria is the hallmark of NDI. Urine volumes range from 3–20 L/day in severe hereditary forms and typically 3–8 L/day in acquired disease. Urine is consistently dilute, with a specific gravity below 1.005 and osmolality below 300 mOsm/kg. Intact thirst drives compensatory polydipsia — patients consume large quantities of fluid to match their output.
Hypernatremia Risk
When access to free water is restricted — in infants, the elderly, or patients with altered consciousness — the inability to concentrate urine combined with ongoing losses rapidly produces dangerous hypernatremia. Neurological sequelae include seizures, intracranial hemorrhage, and coma.
Presentation in Infants (Hereditary NDI)
Male infants with X-linked NDI present in the first weeks of life with unexplained fever, irritability, poor feeding, failure to thrive, and constipation. Repeated hypernatremic episodes before diagnosis cause mental and developmental delay even with eventual treatment. Genetic testing can confirm the diagnosis when NDI is suspected in a family: in a 315-patient European cohort, mutation testing had been done in 86% of patients and found a disease-causing variant in 96% of those tested (Lopez-Garcia 2020).
Presentation in Adults
Adults with acquired NDI generally experience milder symptoms: fatigue, disrupted sleep due to nocturia, and social inconvenience from constant thirst and urination. A desmopressin (DDAVP) challenge cleanly distinguishes NDI (no urine osmolality response) from central DI (marked response) and primary polydipsia (ability to concentrate after water deprivation).
Diagnosis: Water Deprivation and DDAVP Test
The formal water deprivation test, followed by a DDAVP challenge, remains the standard approach to diagnosing and classifying DI.
Step 1 — Water Deprivation
The patient fasts from fluids under continuous supervision. Hourly measurements are made of urine osmolality, urine output volume, plasma osmolality, and body weight. The deprivation phase is terminated when any of the following occur:
- Urine osmolality is stable on three consecutive hourly measurements.
- Body weight falls by more than 5% from baseline.
- Plasma osmolality rises above 295–300 mOsm/kg.
At the end of dehydration: normal subjects and patients with primary polydipsia concentrate urine to above 800 mOsm/kg. Patients with any form of DI typically plateau below 300 mOsm/kg.
Step 2 — DDAVP Challenge
Desmopressin (DDAVP) 2 mcg by intramuscular injection (IM) or 10–20 mcg intranasal is administered at the end of water deprivation. Urine osmolality is measured 1–2 hours later:
- Central DI: urine osmolality increases by more than 50% (often exceeding 200%) — the kidneys can respond to exogenous ADH, confirming a pituitary/hypothalamic source of ADH deficiency.
- NDI (complete): urine osmolality shows minimal or no increase (less than 50%) — the collecting duct does not respond regardless of ADH levels.
- Partial NDI: intermediate response; requires clinical correlation with plasma ADH levels and genetic testing.
Copeptin Assay (Emerging Alternative)
Copeptin is a stable surrogate marker for vasopressin released in equimolar amounts from the posterior pituitary. Direct plasma copeptin measurement can distinguish NDI from central DI without the discomfort and risk of prolonged water deprivation: copeptin is markedly elevated in NDI (high endogenous ADH that the kidneys ignore) and low in central DI (insufficient ADH production).
In a 2018 study at 11 medical centres, 144 patients with large volumes of dilute urine underwent both the indirect water-deprivation test and a hypertonic (strong) salt-water infusion test with copeptin measured once blood sodium reached at least 150 mmol/L. The copeptin test (cutoff above 4.9 pmol/L) gave the correct diagnosis in 96.5% of the 141 patients analysed, against 76.6% for water deprivation. One serious side effect (low blood sodium caused by desmopressin, needing hospital care) occurred during the water-deprivation test. The final diagnoses were primary polydipsia in 82 patients, central DI in 59 and NDI in only 3, so the study mainly tested how well copeptin separates central DI from primary polydipsia (Fenske 2018).
Treatment and Management
1. Treating the Underlying Cause
Where possible, treatment removes the causing drug (lithium, demeclocycline), corrects hypercalcemia or hypokalemia, relieves urinary obstruction, or treats the underlying infiltrative or hematologic disease. Partial or complete NDI resolution depends on how reversible the collecting duct injury is.
2. Low-Sodium, Low-Protein Diet
Reducing dietary sodium to below 100 mEq/day and moderately restricting protein decreases the total osmotic load that must be excreted in urine. This directly reduces the obligatory urine volume. Combined with thiazide therapy, dietary modification can reduce polyuria by approximately 50%.
3. Hydrochlorothiazide (Thiazide Diuretic)
Thiazides act by a paradoxical mechanism: mild volume depletion stimulates compensatory proximal tubular sodium and water reabsorption, delivering less fluid to the distal nephron and collecting duct. The net result is reduced urine output despite the diuretic classification. Doses of 25–50 mg/day are described. It is often combined with amiloride, which limits potassium loss; Boton 1987 notes that potassium supplements are usually required to prevent low potassium (hypokalemia) when thiazides are used alone for lithium-induced polyuria.
4. Amiloride
Amiloride is the drug of choice for lithium-induced NDI. It blocks ENaC, preventing lithium uptake into principal cells. It also counteracts thiazide-induced potassium wasting. Standard dose: 5–10 mg/day.
5. Indomethacin
Prostaglandin E2 (PGE2) normally antagonizes ADH signaling in the collecting duct. Indomethacin suppresses PGE2, modestly enhancing residual ADH sensitivity and concentrating ability. The effect is additive with thiazide. Indomethacin carries gastrointestinal (stomach ulcers and bleeding), kidney and cardiovascular risks, which weigh most heavily in people with chronic kidney disease (CKD) or peptic ulcer disease.
6. Desmopressin (DDAVP)
DDAVP provides no benefit in complete NDI (no functional V2 receptor or AQP2). In partial NDI — where residual receptor function persists — desmopressin may meaningfully reduce urine volume. In partial NDI confirmed by testing, whether desmopressin helps a given person is judged from a supervised trial of the drug.
7. Adequate Free Water Access
Ensuring unrestricted access to free water is critical across all forms of NDI to prevent hypernatremia. In infants with hereditary NDI, formula composition is adjusted to provide sufficient free water for the high obligate urinary losses; low-solute formulas are often required.
Prognosis and Special Populations
Hereditary NDI
Early diagnosis and adequate free water protect against the brain injury of repeated dehydration. In the largest study of inherited NDI (315 patients from 22 countries, median age at diagnosis 0.6 years), adult height was normal, but obesity was more common than the European average (41% vs 16%), mental health problems were reported in 36% of patients (mostly attention-deficit hyperactivity disorder, 16%), and patients aged 25 and over were less likely to hold a university degree (21% vs 35%), although full-time employment was similar. The authors describe an overall favourable outcome, yet more than half had urological and/or mental health problems (Lopez-Garcia 2020). Delayed or missed diagnosis in infancy causes hypernatremic brain injury, leading to intellectual disability, motor deficits, and growth retardation even after eventual treatment. In the same cohort, chronic kidney disease of stage 2 or worse was present in 32% of children and 48% of adults, mostly mild to moderate. Chronic high urine volumes can cause bladder and upper urinary tract dilation (megacystis, megaureter, hydronephrosis), requiring urological monitoring; signs of this (flow uropathy) were found in 38% of the cohort. More children than adults (85% vs 54%) were taking medicines to reduce urine output.
Acquired NDI
Prognosis mirrors reversibility of the underlying cause. Lithium-induced NDI is often partially reversible following drug discontinuation, though some patients with prolonged exposure retain permanent concentrating defects. Hypercalcemia-induced NDI is typically fully reversible once calcium is normalized. Post-obstructive NDI resolves over days to weeks after obstruction relief.
Pregnancy
Normal pregnancy increases vasopressin clearance due to placental vasopressinase. In women with pre-existing NDI, polyuria may worsen substantially. Thirst remains intact, protecting against severe hypernatremia in ambulatory patients, but close monitoring of fluid balance and plasma sodium is required, especially peripartum.
Elderly Patients
Older adults are at particular risk for dangerous hypernatremia from unrecognized NDI because of age-related blunting of the thirst mechanism. Even modest fluid restriction — illness, hospitalization, reduced mobility — can precipitate severe hypernatremia with high associated morbidity and mortality. Unexplained hypernatremia or large urine volumes in an older adult can be a sign of NDI.
Key Research Papers
- — van Lieburg AF, Verdijk MA, Knoers VV, et al. Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet. 1994;55(4):648-52. — PubMed PMID: 7524315
- — Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 1994;264(5155):92-5. — PubMed PMID: 8140421
- — Bichet DG, Arthus MF, Lonergan M, et al. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest. 1993;92(3):1262-8. — PubMed PMID: 8104196
- — Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995;95(4):1838-45. — PubMed PMID: 7535800
- — Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10(5):329-45. — PubMed PMID: 3314489
- — Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol. 2010;23 Suppl 16:S43-8. — PubMed PMID: 21170888
- — Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis. 2006;13(2):96-104. — PubMed PMID: 16580609
- — Morello JP, Bichet DG. Nephrogenic diabetes insipidus. Annu Rev Physiol. 2001;63:607-30. — PubMed PMID: 11181969
- — Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018;379(5):428-439. — PubMed PMID: 30067922
- — Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 2001;16(12):1146-52. — PubMed PMID: 11793119
- — Verbalis JG. Diabetes insipidus. Rev Endocr Metab Disord. 2003;4(2):177-85. — PubMed PMID: 12766546
- — Lopez-Garcia SC, Downie ML, Kim JS, et al. Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2020 (published online 26 December 2020). — PubMed PMID: 33367818
- — Levtchenko E, Ariceta G, Arguedas Flores O, et al. International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance). Nat Rev Nephrol. 2025;21(2):83-96. — PubMed PMID: 39438674
Connections
- Nephrology & Hepatology
- Bartter Syndrome — Acquired NDI with hypokalemia and renal tubular dysfunction
- Gitelman Syndrome — Renal tubular disorder causing electrolyte imbalances
- Alport Syndrome — Hereditary nephropathy with glomerular and tubular involvement
- Endocrine Diseases — Diabetes insipidus differential diagnosis and related endocrine disorders
- Potassium — Hypokalemia as a cause of acquired NDI
- Lab Tests — Urine osmolality, serum sodium, and water deprivation testing